Agencies, societies and charities at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
21 agencies, societies and charities are at ESGCT 2026 — 27 presentations on the program. Most represented: Paul-Ehrlich-Institut (6 on the program), Cell and Gene Therapy Catapult (2 on the program), National Institutes of Health (2 on the program). 7 of them have their own page in this guide. As of Oct 16, 2026.
Topic
Top represented
Showing 1–16 of 21 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
Paul-Ehrlich-Institut Langen, Germany | |
German federal agency for vaccines and biomedicines that authorizes gene and cell therapies and researches targeted viral and lipid vectors. | Workshop Tue Oct 27 9:05am–10:45am Targeted lentiviral vectors for in vivo CAR-T cell generation Vectors and delivery (AAV, lentiviral, LNP)Cell therapies and CAR-T Poster Wed Oct 28 1:30pm–3:30pm An Alternative Approach for In Vivo T Cell Activation Talk Wed Oct 28 3:30pm–5:30pm Off-the-shelf CAR T cells through in vivo gene delivery Cell therapies and CAR-TVectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm Bispecific DART-AAVs: How to engineer vectors for gene delivery into non-activated T cells Poster Thu Oct 29 2:00pm–4:00pm CD56-targeted AAV vectors for receptor-selective gene delivery into NK cells and muscle cells Talk Fri Oct 30 11:15am–1:00pm Elements and priorities for international regulatory harmonization for ATMPs Manufacturing, CMC and access Talk Fri Oct 30 12:00pm–1:00pm ApoE-DARPin fusion proteins enable selective RNA transfer to target cells by lipid nanoparticles Vectors and delivery (AAV, lentiviral, LNP)RNA and oligonucleotide therapies |
Cell and Gene Therapy Catapult London, UK | |
Independent innovation centre helping cell and gene therapy developers translate, scale and manufacture therapies, including a manufacturing centre in Stevenage. | Poster Thu Oct 29 2:00pm–4:00pm Advancing non-viral in vivo gene therapies from innovation to clinical readiness Poster Thu Oct 29 2:00pm–4:00pm Overcoming rAAV gene therapy cost barriers through intensified and continuous manufacturing Poster Thu Oct 29 2:00pm–4:00pm Reducing residual nucleic acid impurities in rAAV production through human nuclease overexpression |
National Institutes of Health Bethesda, MD | |
US federal agency that funds and conducts biomedical research, including gene and cell therapy. | Poster Wed Oct 28 1:30pm–3:30pm Genotoxic rAAV integrations in mice predicted the mechanism of genotoxic rAAV integrations in humans Talk Thu Oct 29 4:30pm–6:00pm SESSION 9b: Lentiviral vectors/integrative vectors Vectors and delivery (AAV, lentiviral, LNP) |
European Health and Digital Executive Agency (HaDEA) Brussels, Belgium | |
European Commission agency that manages EU health research funding, including Horizon Europe health calls on advanced therapies. | Talk Fri Oct 30 9:00am–10:30am European Union funding opportunities for Advanced Therapies in Horizon Europe, Cluster 1 Health Manufacturing, CMC and access Chair Fri Oct 30 9:00am–10:30am SESSION 11d: Building the Horizon: European funding for the Cell and Gene Therapies of today and tomorrow Manufacturing, CMC and access |
European Research Council Brussels, Belgium | |
EU funder of investigator-led frontier research across all fields, including gene and cell therapy. | Chair Fri Oct 30 9:00am–10:30am SESSION 11d: Building the Horizon: European funding for the Cell and Gene Therapies of today and tomorrow Manufacturing, CMC and access Talk Fri Oct 30 9:00am–10:30am The European Research Council’s funding opportunities: current developments and future outlook Manufacturing, CMC and access |
Alliance for Regenerative Medicine Washington, DC | |
International advocacy organisation for the cell and gene therapy sector, representing developers, investors and patient groups on policy and access. | Workshop Tue Oct 27 10:00am–11:00am Real world evidence generation for MAA and HTA Manufacturing, CMC and accessClinical trials and translation |
Association of Research-Based Pharmaceutical Companies (vfa) Berlin, Germany | |
Trade association representing research-based pharmaceutical companies in Germany. | Poster Thu Oct 29 2:00pm–4:00pm Monitoring the National Strategy for Gene and Cell-Based Therapies: Assessing Germany’s Competitiveness and the Impact of Strategic Interventions in a Global Context Manufacturing, CMC and access |
Austrian Federal Office for Safety in Health Care (BASG) Vienna, Austria | |
Austria's medicines regulator, operated by the AGES medicines agency; it authorises clinical trials and medicines, including advanced therapies. | Chair Fri Oct 30 11:00am–1:00pm SESSION 12c: Regulatory & Ethics Manufacturing, CMC and access |
BR Belgian Red Cross | |
Poster Thu Oct 29 2:00pm–4:00pm T-cells maintain phenotype during successful culture in human platelet lysate | |
CTNNB1 Foundation Ljubljana, Slovenia | |
Patient non-profit for CTNNB1 syndrome that is developing an AAV9 gene therapy, now in a first-in-human clinical trial. | Poster Wed Oct 28 1:30pm–3:30pm First-in-human clinical trial of AAV9-mediated gene augmentation therapy for CTNNB1 neurodevelopmental syndrome |
European Commission DG Research and Innovation Brussels, Belgium | |
European Commission department that sets EU research policy and runs the Horizon Europe funding programme. | Talk Fri Oct 30 9:00am–10:30am Horizon Europe for Advanced Therapies: Current EU Landscape and Future Directions Manufacturing, CMC and access |
European Innovation Council Brussels, Belgium | |
EU programme that funds and invests in breakthrough technologies and startups, including cell and gene therapy companies. | Talk Fri Oct 30 9:00am–10:30am Strengthening the Cell and Gene Therapy Pipeline with European Innovation Council support Manufacturing, CMC and access |
European Medicines Agency Amsterdam, Netherlands | |
EU agency that evaluates and supervises medicines, including advanced therapies through its Committee for Advanced Therapies. | Talk Fri Oct 30 12:30pm–1:00pm Academic ATMP development to marketing authorization: Lenti-WAS (pCCL-CT-WAS) in Wiskott-Aldrich syndrome Manufacturing, CMC and accessRare and inherited disease |
Political and economic union of 27 European countries whose institutions set medicines law and fund research. | Workshop Tue Oct 27 11:15am–1:00pm The ATMP centers of excellence and EU biotech-act Manufacturing, CMC and access |
European University Hospital Alliance Brussels, Belgium | |
Alliance of eleven European university hospitals working together on research, education, rare diseases and innovative therapies. | Workshop Tue Oct 27 12:15pm–1:00pm CLINICAL TRIALS AND COMMERCIALISATION WORKSHOP 2 Manufacturing, CMC and access |
Fondazione Telethon Rome, Italy | |
Italian rare disease charity that funds research, runs the Tigem and SR-Tiget institutes and brings gene therapies to patients on a not-for-profit model. | Workshop Tue Oct 27 11:35am–1:00pm Not for profit model of ATMP commercialization in EU and US Manufacturing, CMC and access |
Instantly find 20 buyers from agencies, societies and charities
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESGCT 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction